Isofol Medical Cash Per Share vs. Total Debt
| ISOFOL Stock | SEK 2.40 0.10 4.00% |
For Isofol Medical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Isofol Medical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Isofol Medical AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Isofol Medical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Isofol Medical AB over time as well as its relative position and ranking within its peers.
Isofol |
Isofol Medical AB Total Debt vs. Cash Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Isofol Medical's current stock value. Our valuation model uses many indicators to compare Isofol Medical value to that of its competitors to determine the firm's financial worth. Isofol Medical AB is currently regarded as number one stock in cash per share category among its peers. It also is considered the number one company in total debt category among its peers making up about 118,280 of Total Debt per Cash Per Share. Comparative valuation analysis is a catch-all model that can be used if you cannot value Isofol Medical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Isofol Medical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Isofol Total Debt vs. Cash Per Share
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Isofol Medical |
| = | 0.93 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Isofol Medical |
| = | 110 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Isofol Total Debt vs Competition
Isofol Medical AB is considered the number one company in total debt category among its peers. Total debt of Biotechnology industry is currently estimated at about 788.73 Million. Isofol Medical adds roughly 110,000 in total debt claiming only tiny portion of stocks in Biotechnology industry.
Isofol Medical Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Isofol Medical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Isofol Medical will eventually generate negative long term returns. The profitability progress is the general direction of Isofol Medical's change in net profit over the period of time. It can combine multiple indicators of Isofol Medical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Isofol Medical AB , a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden. Isofol Medical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 12 people.
Isofol Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Isofol Medical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Isofol Medical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Isofol Medical's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Isofol Medical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Forecasting Now
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum |
| All Next | Launch Module |
Use Investing Themes to Complement your Isofol Medical position
In addition to having Isofol Medical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hybrid Mix Funds Thematic Idea Now
Hybrid Mix Funds
Funds or Etfs that are made of portfolios of stocks, bonds, or cash instruments with different maturity horizons and characteristics. The Hybrid Mix Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hybrid Mix Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Isofol Stock
To fully project Isofol Medical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Isofol Medical AB at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Isofol Medical's income statement, its balance sheet, and the statement of cash flows.